In a significant advancement in the fight against colorectal cancer, a team of researchers led by Indian Australian scientist Dr Ashwini Chand at La Trobe University’s Cancer Medicine department has uncovered the anti-cancer potential of Bazedoxifene.
Published in the esteemed journal Cell Death & Disease, the study introduces a promising new avenue for treating one of the most common and lethal forms of cancer worldwide.
Bazedoxifene, initially developed as a modulator of estrogen signalling, was found to inhibit the action of two major pro-inflammatory signalling molecules, IL-6 and IL-11. This discovery marks a pivotal shift in the drug’s potential applications. It highlights its capability as a formidable anti-cancer agent against colorectal cancer through a mechanism distinct from its original purpose.
Dr Chand, the study’s lead researcher, shared insights into the groundbreaking research,
“This study expands on that knowledge by demonstrating Bazedoxifene’s efficacy in suppressing the growth of human colorectal cancer models.”
“Our findings are rooted in the previously unearthed potential of Bazedoxifene to block critical pro-inflammatory signalling pathways.”
Dr. Rhynelle Dmello, a former PhD student under Dr. Chand and the first author of the study, elaborated on the research’s implications, stating, Our research defines potential drug combinations that could further enhance Bazedoxifene’s effectiveness as an anti-cancer agent.”
“The suppression of cancer growth we observed with Bazedoxifene alone was compelling.”
The study not only sheds light on the novel anti-cancer properties of Bazedoxifene but also opens the door to developing more effective treatment strategies through combination therapies. The researchers are optimistic about the drug’s future in oncology, especially with further research and the prospect of clinical trials.
This groundbreaking research was made possible through a multi-institutional collaboration, involving prestigious institutions such as The Walter and Eliza Hall Institute of Medical Research, the University of Melbourne, Bio21 Institute, St. Vincent’s Institute of Medical Research, and the Barcelona Institute of Science and Technology.
The discovery of Bazedoxifene’s potential as an anti-cancer agent represents a beacon of hope for patients battling colorectal cancer. With ongoing research and eventual clinical trials, this could signify a major leap forward in the quest for more effective cancer treatments.
The scientific community and patients alike await the next phases of research with bated breath, hopeful for a future where colorectal cancer can be combated more effectively.
Support Our Journalism
Global Indian Diaspora needs fair, non-hyphenated, and questioning journalism, packed with on-ground reporting. The Australia Today – with exceptional reporters, columnists, and editors – is doing just that. Sustaining this needs support from wonderful readers like you.
Whether you live in Australia, the United Kingdom, Canada, the United States of America, or India you can take a paid subscription by clicking Patreon Buy an annual ‘The Australia Today Membership’ to support independent journalism and get special benefits.
